The hosts discuss a major new systematic review in the American Journal of Sports Medicine evaluating PRP for knee osteoarthritis, highlighting statistically significant improvements in pain and function at early and mid-term follow-up. Yet they emphasize that progress in orthobiologics is hampered by poor reporting of PRP preparation, wide heterogeneity among commercial systems, and inconsistent comparator choices. They explore how placebo effects—from the injection itself to the theatrics of PRP preparation—can meaningfully inflate outcomes and obscure true treatment effects. Their conversation calls for rigorous blinding, larger and better-controlled trials, and improved transparency in how PRP is formulated and delivered to clarify whether observed benefits stem from biology, psychology, or both.